![](/fileadmin/_processed_/csm_china_vs_usa_boxing-web_647d130897.jpg)
BIOSECURE Act could affect half of US biopharmaceutical development
In January 2024, the US Senate and House of Representatives introduced the BIOSECURE Act to prevent US companies that collaborate with "foreign...
![](/fileadmin/_processed_/csm_NCI-radiopharma_21ffe1bccf.png)
ITM gets equity to launch Phase III lead radiopharmaceutical ITM-11
Radiopharma conjugate specialist Isotope Technologies Munich SE has raised €188m in an equity financing led by globally active investor Temasek....
![](/fileadmin/_processed_/csm_CellugyAS_76a73a84dd.png)
Seed financing for Cellugy A/S
Denmark's Cellugy will use an €4.9m seed financing to scale up of its bio-fabricated dry cellulose production platform aimed at replacing...
![](/fileadmin/_processed_/csm_capsule_by_design_exvolvo-web_5315d0b612.jpg)
No more needles - Exvolvo arises with help of Verily and NLC Health
NLC Health Ventures launches a new early-stage drug delivery company. The venture builder from The Netherlands partners with Verily from which Exolvo...
![](/fileadmin/_processed_/csm_Electrochea_process_c40cabeed1.png)
Electrochaea sells biomethane reactor to Again A/S
Like German bio-CH4 producer Electrochea GmbH, Danish Again A/S is using CO2-fxing archaea, but to manufacture carbon-negative chemicals such...
![](/fileadmin/_processed_/csm_valneva_lab-web-STA_3217-scaled_e65f26fc69.jpg)
Valneva gets approval for Chikungunya vaccine in Canada
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) announced today that Health Canada has approved IXCHIQ®, Valneva's single-dose vaccine for the...
![](/fileadmin/_processed_/csm_RNA_IQVIA_18a4c7238b.png)
Wacker Chemie AG opens €100m RNA manufacturing site
With a new production facility, which Wacker Chemie subsidiary Wacker Biotech calls an RNA competence centre and whose construction costs are...